• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·GXI.DE
Share

Gerresheimer AG Stocks

€ 25.38Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

€ 982.87M

€ 25.38
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. Its Plastics & Devices segment provides a variety of drug administration tools, such as inhalers, insulin pen systems, prefillable syringes, and diagnostic systems, for the pharmaceutical, biotech, diagnostics, and medical technology sectors. This division also manufactures plastic containers, closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and related accessories for solid, liquid, and ophthalmic applications, alongside bottles for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging products for the pharmaceutical and cosmetics industries, including infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; and miniature bottles for liquid food, spices, spirits, fragrances, deodorants, skincare, and wellness products. Lastly, the Advanced Technologies division focuses on developing intelligent drug delivery systems, like micro pumps, designed to enable the self-administration of medication for conditions such as Parkinson's disease or heart failure, serving its pharmaceutical and biotech clients.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of GXI.DE is 22 and suggests 12% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to dec

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026